Drugs / Irbesartan
Irbesartan
also known as
Aprovel · Irb · Avapro · BMS-186295 · I150 · I300 · Ifirmasta · Ifirmasta (previously irbesartan krka) · +17 more
Small molecule targets AGTR1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | AVAPRO | — | 2001-05-26 – 2002-09-17 | fda.gov ↗ |
| Approved | US (FDA) | AVALIDE | — | 1997-09-30 | fda.gov ↗ |
| Approved | EU (EMA) | Aprovel | — | 1997-08-26 | europa.eu ↗ |
Trials 67 · started per year
today
EU approved 1997
US approved 1997
1
3
6
10
8
7
2
2
3
1
2
2
3
1
2
3
1
1
2
5
1
199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03016832 | Jan 2017 → May 2018 | diabetic kidney disease | Jiangsu Famous Medical Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT05688085 | Oct → Dec 2022 | — | Handok Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05688098 | Sep → Nov 2022 | — | Handok Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05663073 | Sep → Dec 2022 | — | Handok Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03934307 | May 2019 → Apr 2022 | hypertensive disorder | Alnylam Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01825850 | Jun → Sep 2013 | — | LG Life Sciences | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02380625 | Apr 2015 → Jan 2016 | Ebola hemorrhagic fever | Clinical Research Management, Inc. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04488978 | May 2020 → Nov 2021 | essential hypertension | Handok Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01949233 | Oct 2013 → Oct 2015 | Marfan syndrome | University of Oxford | Unknown | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT00106561 | Jan 2002 → Sep 2004 | diabetic kidney disease, glomerulonephritis, proteinuria | Melbourne Health | Completed | No outcome recorded |
| Phase 2/3 | NCT00389168 | Apr 1995 → Apr 1997 | hypertensive disorder | Karolinska Institutet | Completed | No outcome recorded |
| Phase 320 trials · 3 met primary · 4 missed | ||||||
| Phase 3 | NCT05475665 | Jul 2022 → Mar 2023 | essential hypertension | Handok Inc. | Completed | Met primary |
| Phase 3 | NCT04606563 | Oct 2020 → Apr 2022 | COVID-19 | University of British Columbia | Terminated | Missed primary |
| Phase 3 | NCT02735707 | Apr 2016 → Feb 2026 overdue | pneumonia | UMC Utrecht | Recruiting | Mixed |
| Phase 3 | NCT01992796 | Jan 2014 → Jan 2017 | infectious disease with sepsis | University of Salerno | Unknown | No outcome recorded |
| Phase 3 | NCT01625494 | May 2012 → Jan 2013 | hypertensive disorder | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01442987 | May 2011 → Apr 2013 | hyperlipidemia, hypertensive disorder | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 3 | NCT00933231 | Aug 2009 → May 2015 | — | Astellas Pharma Inc | Completed | Missed primary |
| Phase 3 | NCT00957554 | Jul 2009 → Sep 2010 | hypertensive disorder | Sanofi | Completed | Met primary |
| Phase 3 | NCT00956644 | Jul 2009 → Aug 2010 | essential hypertension | Sanofi | Completed | Met primary |
| Phase 3 | NCT00265642 | Oct 2006 → Apr 2013 | chronic hepatitis C virus infection | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT00296218 | Feb 2006 → Mar 2007 | hypertensive disorder, myocardial ischemia | Sanofi | Completed | Missed primary |
| Phase 3 | NCT00225667 | Dec 2005 → Jul 2007 | atrial fibrillation, hypertensive disorder | Connolly, Stuart, M.D. | Unknown | No outcome recorded |
| Phase 3 | NCT00263003 | Jun 2005 → ? | hypertensive disorder | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00095550 | Oct 2004 → Jun 2005 | hypertensive disorder | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00095394 | Sep 2004 → May 2005 | hypertensive disorder | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00171080 | Apr 2004 → Mar 2006 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00561964 | Jan 2004 → Jul 2005 | hypertensive disorder | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00249795 | Jun 2003 → Aug 2009 | atrial fibrillation | Sanofi | Completed | Missed primary |
| Phase 3 | NCT00317915 | — | hypertensive disorder, proteinuria, type 2 diabetes mellitus | Steno Diabetes Center Copenhagen | Completed | No outcome recorded |
| Phase 3 | NCT00005010 | ? → Mar 2004 | chronic transplant rejection, end stage renal failure | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 428 trials · 2 met primary · 1 missed | ||||||
| Phase 4 | NCT05377203 | Jul 2022 → Jul 2023 | hypertensive disorder | The Third Xiangya Hospital of Central South University | Completed | Met primary |
| Phase 4 | NCT03147677 | Jul 2016 → Jul 2018 | diabetic kidney disease | The Third Xiangya Hospital of Central South University | Completed | No outcome recorded |
| Phase 4 | NCT02817360 | Feb 2016 → Dec 2025 overdue | heart disorder, type 2 diabetes mellitus | Martin Huelsmann | Recruiting | No outcome recorded |
| Phase 4 | NCT02539810 | Sep 2015 → Dec 2016 | renal artery atheroma, resistant hypertension | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| Phase 4 | NCT01500590 | Nov 2011 → Aug 2018 | hypertensive disorder, type 2 diabetes mellitus | Hospital Authority, Hong Kong | Unknown | No outcome recorded |
| Phase 4 | NCT00670566 | Apr 2008 → Mar 2009 | hypertensive disorder | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00517322 | Aug 2007 → Aug 2010 | hypertensive heart disease | University of Insubria | Unknown | No outcome recorded |
| Phase 4 | NCT00500604 | Jul 2007 → Jan 2010 | hypertensive disorder | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00443612 | Sep 2006 → Oct 2008 | hypertensive disorder | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00334581 | May 2006 → Jun 2008 | hypertensive disorder | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00362037 | Mar 2006 → Jun 2008 | essential hypertension | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00335673 | Feb → Nov 2006 | hypertensive disorder | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00362258 | Feb 2006 → Sep 2008 | hypertensive disorder | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00110422 | Nov 2005 → Feb 2007 | hypertensive disorder, metabolic syndrome X | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 4 | NCT00535925 | Oct 2005 → Dec 2011 | diabetic kidney disease | University of Campania Luigi Vanvitelli | Completed | No outcome recorded |
| Phase 4 | NCT00265967 | Sep 2005 → Feb 2007 | hypertensive disorder | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00283036 | Apr 2005 → ? | hypertensive disorder | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00125645 | Mar 2005 → Sep 2011 | myocardial infarction | University of Southern Denmark | Completed | No outcome recorded |
| Phase 4 | NCT00350038 | Feb 2005 → Aug 2007 | hyperlipidemia, hypertensive disorder | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00185055 | Nov 2004 → Feb 2005 | — | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 4 | NCT00095290 | Sep 2004 → Nov 2005 | proteinuria | Bristol-Myers Squibb | Completed | Missed primary |
| Phase 4 | NCT00264212 | Aug 2004 → ? | hypertensive disorder | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00347087 | Jul 2004 → Jun 2007 | heart failure | Charite University, Berlin, Germany | Completed | Met primary |
| Phase 4 | NCT00847834 | Dec 2003 → Jun 2004 | essential hypertension | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00549133 | Oct 2003 → Apr 2005 | essential hypertension, type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00320879 | Sep 2003 → Nov 2004 | proteinuria, type 2 diabetes mellitus | Steno Diabetes Center Copenhagen | Completed | No outcome recorded |
| Phase 4 | NCT00562809 | Jul 2003 → Aug 2004 | hypertensive disorder | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00529750 | Jul 2002 → Jan 2005 | hypertensive disorder | Sanofi | Completed | No outcome recorded |
| Phase not applicable8 trials | ||||||
| — | NCT06790927 | Feb 2025 → Dec 2026 expected | hypertensive disorder | Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
| — | NCT01858610 | Mar → Apr 2013 | — | Damanhour University | Completed | No outcome recorded |
| — | NCT01519297 | May 2012 → Jul 2017 | preeclampsia | Brigham and Women's Hospital | Suspended | No outcome recorded Stop: Business |
| — | NCT01195818 | Sep 2010 → Sep 2014 | sickle cell disease | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| — | NCT00742066 | Mar 2008 → Jul 2009 | essential hypertension | Maastricht University Medical Center | Unknown | No outcome recorded |
| — | NCT00212901 | Aug 2004 → Sep 2006 | diabetic kidney disease | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| — | NCT00154024 | Mar 2003 → Oct 2006 | — | Technical University Dresden | Completed | No outcome recorded |
| — | NCT00180024 | Jan 2002 → Sep 2005 | — | Technical University Dresden | Completed | No outcome recorded |
| Comparator or background therapy44 trials | ||||||
| Phase 2 | NCT07555054 Comparator | May 2026 → Nov 2027 expected | chronic kidney disease | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06635772 Comparator | Nov 2024 → Dec 2025 overdue | IgA glomerulonephritis | Hansoh BioMedical R&D Company | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05670028 Background | Jun 2023 → Jan 2026 | ischemic stroke, vascular insufficiency disorder | Beijing Tiantan Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02386293 Comparator | Apr 2014 → Nov 2019 | hypertensive disorder, obesity disorder | Augusta University | Unknown | No outcome recorded |
| Phase 2 | NCT01613118 Comparator | Mar 2014 → Jun 2016 | focal segmental glomerulosclerosis | Travere Therapeutics, Inc. | Completed | Met primary |
| Phase 2 | NCT01968759 Background | Oct 2013 → Oct 2015 | chronic kidney disease | Mario Negri Institute for Pharmacological Research | Completed | Missed primary |
| Phase 2 | NCT00950066 Comparator | Jul 2009 → Jan 2010 | essential hypertension | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00635232 Comparator | Mar → Nov 2008 | hypertensive disorder | Ligand Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT05272878 Comparator | Nov 2022 → Jun 2025 overdue | acute kidney injury | Assistance Publique - Hôpitaux de Paris | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05476354 Comparator | Jul 2022 → Apr 2023 | essential hypertension | Handok Inc. | Completed | Met primary |
| Phase 3 | NCT05056727 Background | Sep 2021 → Feb 2024 | chronic kidney disease | AstraZeneca | Terminated | Missed primary Stop: Enrollment |
| Phase 3 | NCT03762850 Comparator | Dec 2018 → Aug 2023 overdue | IgA glomerulonephritis | Travere Therapeutics, Inc. | Active not recruiting | Met primary |
| Phase 3 | NCT03660397 Background | Aug 2018 → Jul 2019 | hypertensive disorder | Third Military Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT03493685 Comparator | Apr 2018 → Mar 2023 | focal segmental glomerulosclerosis | Travere Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02597361 Comparator | Jan 2016 → Feb 2020 | Ehlers-Danlos syndrome, vascular type | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT00152698 Comparator | Nov → Dec 2009 | hyperlipoproteinemia | University of Erlangen-Nürnberg Medical School | Withdrawn | No outcome recorded |
| Phase 3 | NCT00791830 Comparator | Apr 2009 → Jan 2013 | chronic renal failure syndrome | University of Aarhus | Completed | No outcome recorded |
| Phase 3 | NCT00657059 Comparator | Sep 2007 → May 2019 | IgA glomerulonephritis | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 3 | NCT00352560 Comparator | Jul 2006 → Jun 2007 | atrial fibrillation | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00095238 Comparator | Jun 2002 → Jul 2008 | congestive heart failure | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 4 | NCT07547878 Comparator | Apr 2026 → Mar 2029 expected | chronic kidney disease, type 2 diabetes mellitus | Baylor Research Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06660940 Background | Oct 2024 → Oct 2027 expected | diabetic kidney disease, diabetic retinopathy | Chinese PLA General Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05243199 Comparator | Aug 2020 → Mar 2023 | end stage renal failure, heart failure | Ruijin Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04394117 Comparator | Jun 2020 → Nov 2021 | COVID-19 | The George Institute | Completed | No outcome recorded |
| Phase 4 | NCT04330300 Comparator | Apr 2020 → Jul 2021 | COVID-19, essential hypertension | National University of Ireland, Galway, Ireland | Suspended | No outcome recorded Stop: Business |
| Phase 4 | NCT02842359 Comparator | Aug 2016 → Apr 2018 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT04061824 Comparator | May 2016 → Dec 2018 | hyperlipidemia, hypertensive disorder | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT01588795 Comparator | Apr 2012 → Jan 2016 | diabetic kidney disease, proteinuria | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 4 | NCT00987662 Comparator | Jan 2012 → Jan 2013 | hypertensive disorder, obesity disorder | Aristotle University Of Thessaloniki | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT01360710 Comparator | Jan 2012 → Jan 2014 | abdominal obesity-metabolic syndrome, hypertensive disorder | Baker Heart and Diabetes Institute | Unknown | No outcome recorded |
| Phase 4 | NCT01377285 Background | Jun 2010 → Dec 2018 | chronic renal failure syndrome | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00613496 Comparator | May 2009 → May 2010 | persistent atrial fibrillation | University of Magdeburg | Unknown | No outcome recorded |
| Phase 4 | NCT00741585 Comparator | Sep 2008 → Jun 2018 | chronic kidney disease, essential hypertension, stroke disorder | University of Vigo | Completed | No outcome recorded |
| Phase 4 | NCT00708344 Comparator | Jun 2008 → Jul 2009 | hypertensive disorder | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT01238705 Comparator | Apr 2008 → Oct 2010 | essential hypertension, sexual disorder | LanZhou University | Unknown | No outcome recorded |
| Phase 4 | NCT00660309 Comparator | Apr 2008 → Dec 2009 | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00224549 Background | Apr 2005 → Aug 2009 | essential hypertension | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 4 | NCT00353652 Comparator | Jan 2005 → Jan 2013 | hypertensive disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00564187 Comparator | Feb 2003 → Dec 2004 | hypertensive disorder | Sanofi | Completed | No outcome recorded |
| — | NCT06208072 Comparator | Sep 2023 → Dec 2024 | essential hypertension, obesity disorder | Hippocration General Hospital | Unknown | No outcome recorded |
| — | NCT04981613 Background | Jul 2021 → Aug 2024 | diabetic kidney disease | First Affiliated Hospital Xi'an Jiaotong University | Completed | No outcome recorded |
| — | NCT02644486 Comparator | Jan 2016 → Feb 2018 | glomerular disorder | Zhi-Hong Liu, M.D. | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00794963 Background | Nov 2008 → May 2010 | metabolic syndrome X | Northwell Health | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00684489 Comparator | Sep 2003 → Mar 2005 | essential hypertension | Medical University of South Carolina | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2021-11-13 | Alnylam Pharmaceuticals | Results Alnylam Presents New Data for Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension, at the American Heart Association Scientific Sessions 2021 alnylam.com ↗
Additional results demonstrated that zilebesiran was safe and well tolerated in the Phase 1 study during salt restriction and when administered concomitantly with irbesartan, an oral renin-angiotensin-aldosterone system inhibitor (RAASi). |
| 2019-03-05 | Hanmi Pharmaceutical Company Limited | Results <보도자료> 한미약품 ‘로벨리토’ 4상 결과 국제학술지 등재 hanmi.co.kr ↗
연구 결과에 따르면, 로벨리토를 투여한 환자의 약 86%가 목표혈압과 LDL-C 목표수치에 각각 도달했다. |
| 2018-06-12 | Hanmi Pharmaceutical Company Limited | Results <보도자료> 한미약품, 아모잘탄·로벨리토 임상 결과 유럽고혈압학회 발표 hanmi.co.kr ↗
로벨리토를 투여한 환자군의 약 75%에서 혈압과 LDL-C 목표치를 동시에 달성했다 |
| 2016-11-10 | Hanmi Pharmaceutical Company Limited | Results <보도자료> ‘로벨리토’ 3상 결과 국제학술지 등재 hanmi.co.kr ↗
연구 결과, 병용 투여군은 최대 용량 투여시 93.1%가 LDL-콜레스테롤 목표에, 55.2%가 목표혈압에 도달했다. |
| 2012-09-28 | Sumitomo Pharma America, Inc. | Regulatory Dainippon Sumitomo Pharma obtains manufacturing and marketing approval for "AIMIX Combination Tablets LD/HD" sumitomo-pharma.com ↗ |
| 2012-04-02 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Launch of Generic Avapro® and Generic Avalide® in the United States; Awarded 180-Day Period of Marketing Exclusivity tevapharm.com ↗
As the first company to file Abbreviated New Drug Applications (ANDA) containing paragraph IV certifications for both of these products, Teva has been awarded a 180-day period of marketing exclusivity. |
| 2011-11-30 | Sumitomo Pharma America, Inc. | Regulatory Dainippon Sumitomo Pharma announces application for manufacturing and marketing approval for "DSP-8153", combination product of irbesartan and amlodipine besilate sumitomo-pharma.com ↗
it submitted an application for manufacturing and marketing approval for "DSP-8153" (product code) |
All press releases naming this drug 9 releases
Evidence & citations 30 cited values
Every value below carries the sentence it was read from. 116 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | irbesartan | “Accordingly, we conducted studies in 17 subjects with untreated stage 1 hypertension, measuring sympathetic nerve activity at baseline and after 12 weeks of chlorthalidone...” PMID 22733474 ↗ Jun 2012109“Investigation of wheather addition of angiotensin receptor blocker (Irbesartan) to recommended doses of angiotensin converting enzyme inhibitor (trandolapril) is more effective...” NCT00212901 ↗ “Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker (irbesartan 300mg), a diuretic (furosemide 40mg or indapamide LP 1.5mg according to the...” NCT01588795 ↗ “One of ARBs(Valsartan, Olmesartan, Candesartan, Telmisartan, Fimasartan, Losartan and Irbesartan) and one of statins(Rosuvastatin, Atorvastatin, Pitavastatin, Simvastatin,...” NCT04061824 ↗ “To manipulate the blood pressure within a certain range with hypotensive drugs (e.g. nifedipine, benidipine, captopril, benazepril, irbesartan, labetalol, urapidil) and/or...” NCT05670028 ↗ “Angiotensin II receptor antagonists ,these medicines have names that end in "sartan".For examples:losartan,candesartan,irbesartan,olmesartan,telmisartan,valsartan” NCT01377285 ↗ “amlodipine 5 mg + irbesartan 150mg is used for those who do not meet blood pressure targets after 4 weeks of treatment” NCT06790927 ↗ “ramipril 2.5mg to 10mg once daily if patient experience cough, we will use irbesartan 150 mg to 300mg once daily” NCT01500590 ↗ “participants will receive one table each of Irbesartan and Amlodipine High in a crossover design” NCT05688098 ↗ “Kunxian capsule (2# tid or 2# bid) + irbesartan tablet (150mg qd or 300mg qd) for 48 weeks” NCT04981613 ↗ “Candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan” NCT04330300 ↗ |
| Known as | Aprovel | “Irbesartan (Aprovel)” NCT00362037 ↗ |
| Known as | Avapro | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07547878 ↗ |
| Known as | BMS-186295 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1513 ↗ |
| Known as | I150 | “irbesartan 150 mg [I150] monotherapy administered once daily” PMID 22853847 ↗ Jul 2012 |
| Known as | I300 | “irbesartan (I300) monotherapy” PMID 22853847 ↗ Jul 2012 |
| Known as | Ifirmasta | ChEMBL registry synonym — accepted as the source's own label CHEMBL1513 ↗ |
| Known as | Ifirmasta (previously irbesartan krka) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1513 ↗ |
| Known as | Irb | “PURPOSE: To investigate the pharmacokinetic/pharmacodynamic (PK/PD) interaction between irbesartan (IRB) and hydrochlorothiazide (HCT) in normotensive subjects.” PMID 25545238 ↗ Feb 20152“This study aimed to evaluate the efficacy and tolerability of irbesartan (IRB) and amlodipine (AML) combination therapy” PMID 38704294 ↗ May 2024 “irbesartan (Irb) 150 mg” PMID 18538118 ↗ Jun 2008 |
| Known as | Irbesartan bms | ChEMBL registry synonym — accepted as the source's own label CHEMBL1513 ↗ |
| Known as | Irbesartan component of avalide | ChEMBL registry synonym — accepted as the source's own label CHEMBL1513 ↗ |
| Known as | Irbesartan component of coaprovel | ChEMBL registry synonym — accepted as the source's own label CHEMBL1513 ↗ |
| Known as | Irbesartan component of ibersartan/hydrochlorothiazide ibersartan | ChEMBL registry synonym — accepted as the source's own label CHEMBL1513 ↗ |
| Known as | Irbesartan component of ibersartan/hydrochlorothiazide teva ibersartan | ChEMBL registry synonym — accepted as the source's own label CHEMBL1513 ↗ |
| Known as | Irbesartan component of ibersartan/hydrochlorothiazide zentiva ibersartan | ChEMBL registry synonym — accepted as the source's own label CHEMBL1513 ↗ |
| Known as | Irbesartan component of ifirmacombi | ChEMBL registry synonym — accepted as the source's own label CHEMBL1513 ↗ |
| Known as | IRBESARTAN HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1513 ↗ |
| Known as | Irbesartan teva | ChEMBL registry synonym — accepted as the source's own label CHEMBL1513 ↗ |
| Known as | Irbesartan zentiva | ChEMBL registry synonym — accepted as the source's own label CHEMBL1513 ↗ |
| Known as | Irbesartan zentiva (previously irbesartan winthrop) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1513 ↗ |
| Known as | Irbesartan/Amlodipine FDC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05663073 ↗ |
| Known as | Karvea | ChEMBL registry synonym — accepted as the source's own label CHEMBL1513 ↗ |
| Known as | NSC-758696 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1513 ↗ |
| Known as | Sabervel | ChEMBL registry synonym — accepted as the source's own label CHEMBL1513 ↗ |
| Known as | Sarbevel | ChEMBL registry synonym — accepted as the source's own label CHEMBL1513 ↗ |
| Known as | SR47436 | “IRBESARTAN (SR47436)” NCT00950066 ↗ |
| Action | Inhibit | “Type-1 angiotensin II receptor antagonist” CHEMBL1513 ↗1“AT1-receptor blockade” NCT00152698 ↗ |
| Modality | Small molecule | — CHEMBL1513 ↗ |
| Route | Oral | “Tablets, Oral, titration from 75 to 300 mg, once daily up to 6 years” NCT00095238 ↗ |
| Target | AGTR1 | “Type-1 angiotensin II receptor antagonist” CHEMBL1513 ↗ |